Dupilumab Treatment Normalizes Skin Barrier Function in Children Aged 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Michael J. Cork^{1,2}, Donald Y.M. Leung³, Peck Ong⁴, Simon G. Danby¹, Marco Ramirez-Gama³, Shannon Garcia³, Patricia Taylor³, Joseph Zahn⁵, Amy Praestgaard⁶, Gabriel Bologna⁶, Annie Zhang⁶

¹Sheffield Dermatology Research, University of Sheffield, UK; ²Sheffield, UK; ³National Jewish Health, Denver, CO, USA; ⁴Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA; ⁵Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; ⁶Sanofi, Cambridge, MA, USA

BACKGROUND

- Atopic dermatitis (AD) is associated with significant disruption in skin barrier function, mediated by type 2 inflammatory cytokines interleukin (IL)-4 and IL-13
- Previous studies show that dupilumab treatment in patients over 12 years of age with moderate-to-severe AD improves skin barrier function^{1,2}

RESULTS (CONT.)




Figure 2. Mean EASI (SE) over time in dupilumab-treated patients.

- To report the effect of dupilumab treatment in pediatric patients aged 6-11 years with moderate-to-severe AD on skin barrier function, clinician-, and patient-reported outcomes

METHODS


- PEdiatric skin barrier function and Lipidomics STudy in patients with Atopic Dermatitis (PELISTAD) was an open-label, exploratory study with matched healthy controls on skin barrier function in pediatric patients aged 6–11 years with moderate-to-severe AD
- Patients were treated with dupilumab for 16 weeks based on baseline weight (300 mg every 4 weeks: \geq 15 kg to < 30 kg; 200 mg every 2 weeks: \geq 30 kg to < 60 kg)
- Transepidermal water loss (TEWL) (g/m²/h) was assessed longitudinally after skin tape strippings (STS) from lesional and non-lesional skin of AD patients treated with dupilumab and from healthy skin of matched healthy volunteers
- Eczema Area and Severity Index (EASI) and Children's Dermatology Life Quality Index (CDLQI) were assessed during the same time periods
- For baseline comparisons, *P* values were derived using either independent sample t-tests or non-parametric Wilcoxon Mann Whitney U tests
- For difference from baseline comparisons, *P* values were derived using either paired t-tests or non-parametric Wilcoxon signed rank tests
- Least squares (LS) means were obtained based on mixed models for repeated measures with absolute values as the response variable and baseline values, age, sex, visit, and visit-by-skin type interaction as covariates


RESULTS

90

Figure 1. Improvement in median TEWL after 5 STS over time. - Lesional skin (n = 23)

Figure 3. Mean CDLQI (SE) over time in dupilumab-treated patients.






At baseline, the median TEWL after 5 STS was significantly higher in lesional and non-lesional AD skin compared with healthy skin (P < 0.0001 for both skin types). Median TEWL after 5 STS significantly improved in lesional skin after 16 weeks of dupilumab treatment (P < 0.0001, vs baseline). At Week 16, LS mean TEWL after 5 STS in AD lesional and non-lesional skin reached levels comparable with those of healthy skin (P = 0.942 and P = 0.226, respectively). ****P < 0.0001 vs baseline, for lesional AD skin; $^{+}P < 0.05$, ⁺⁺⁺P < 0.001 vs baseline, for non-lesional AD skin. [#]P < 0.0001 for lesional and non-lesional AD skin vs healthy skin. BL, baseline; CI, confidence interval.

Table. Treatment-emergent adverse events during the treatment period.

n (%)	Dupilumab (n = 23)	Healthy volunteers (n = 18)
Participants with any TEAE	21 (91.3)	6 (33.3)
Participants with any severe TEAE	0	0
Participants with any treatment-emergent SAE	0	0
Participants with any TEAE leading to permanent study intervention discontinuation	0	0
Participants with any TEAE leading to permanent study discontinuation	0	0
Participants with any treatment-emergent AESI	0	0


Figure 4. Improvement in a patient's assessed AD lesional skin at baseline and Week 16.



AESIs include: anaphylactic reactions, systemic hypersensitivity reactions, helminthic infections, any severe type of conjunctivitis or blepharitis, keratitis, clinically symptomatic eosinophilia (or eosinophilia associated with clinical symptoms). AESI, adverse event of special interest; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

CONCLUSION

• Dupilumab treatment normalizes skin barrier function, as assessed by decreased TEWL, and improves clinician- and patient- reported outcomes in pediatric patients aged 6–11 years with moderate-to-severe AD



Baseline

Week 16

Target lesion photos (left) at baseline and Week 16 were analyzed using the TiVi index (right). TiVi is a colorimetric measurement of the skin, linearly linked to the RBC concentration within the skin, which allows the quantification of skin erythema (vasodilatation). The red/yellow hues represent a high concentration of RBC, associated with increased erythema, and the blue/green hues represent low concentration of RBC, associated with decreased erythema.^{3,4} RBC, red blood cells; TiVi, tissue viability imaging.

References: 1. Bissonnette R, et al. Poster presented at EADV 2022. 2. Bissonnette R, et al. Proc SPIE. 2010;7563:75630W. 4. Zhai H et al. Skin Res Technol. 2009;15:14-9. Acknowledgments and funding sources: Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT04718870. Medical writing/editorial assistance was provided by Marie Vidal, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guideline. Photos acquired with the help of Dorian Kaiber using QuantifiCare 3D standardized imaging system. **Disclosures: Cork MJ:** AbbVie, Astellas Pharma, Boots, Dermavant, Galapagos, Galderma, L'Oréal, Menlo Therapeutics, Novartis, Oxagen, Pfizer, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals Inc., Sanofi – investigator and/or consultant. Leung DYM: Boehringer Ingelheim, Evommune, Genentech, Incyte, LEO Pharma – consultant; Sanofi – research grant. Ong P: AbbVie, Incyte, Pfizer, Regeneron Pharmaceuticals Inc. – research grants. Danby SG: Almirall, Hyphens Pharma, Johnson & Johnson, LEO Pharma, L'Oréal, Perrigo, Pfizer, Rohto Pharmaceutical, Sanofi – investigator and/or consultant. Ramirez-Gama M, Garcia S, Taylor P: No conflicts of interest to disclose. Zahn J: Regeneron Pharmaceuticals Inc. – employees, may hold stock and/or stock options in the company. Bologna G: Ividata Life Sciences – employee (contracted by Sanofi).

Presented at the 22nd European Society for Pediatric Dermatology Congress (ESPD 2023); Malaga, Spain; May 4–6, 2023.